PULM Stock Summary and Trading Ideas (Pulmatrix | NASDAQ:PULM)

Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.

Pulmatrix trades on the NASDAQ stock market under the symbol PULM.

As of April 26, 2024, PULM stock price declined to $2.04 with 6,762 million shares trading.

PULM has a market cap of $7.45 million. This is considered a Sub-Micro Cap stock.

Last quarter Pulmatrix reported $2 million in Revenue and -$.57 earnings per share. This beat revenue expectation by $432,000 and exceeded earnings estimates by $.47.

In the last 3 years, PULM stock traded as high as $23.40 and as low as $1.55.

The top ETF exchange traded funds that PULM belongs to (by Net Assets): VXF.

PULM has underperformed the market in the last year with a price return of -25.5% while the SPY ETF gained +27.4%. However, in the short term, PULM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +12.4% vs +4.6% return in SPY. But in the last 2 weeks, PULM shares have been beat by the market, returning -5.6% compared to an SPY return of -0.5%.

PULM support price is $1.96 and resistance is $2.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PULM stock will trade within this expected range on the day.